Analyst Price Targets — TMO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 30, 2026 2:25 pm | — | UBS | $615.00 | $579.86 | TheFly | Thermo Fisher price target raised to $615 from $590 at UBS |
| January 30, 2026 2:08 pm | — | Wells Fargo | $683.00 | $580.09 | StreetInsider | Thermo Fisher Scientific (TMO) PT Lowered to $683 at TD Cowen |
| January 30, 2026 12:27 pm | — | Robert W. Baird | $653.00 | $583.12 | TheFly | Thermo Fisher price target raised to $653 from $645 at Baird |
| January 30, 2026 10:36 am | — | Barclays | $650.00 | $592.16 | TheFly | Thermo Fisher price target raised to $650 from $625 at Barclays |
| January 9, 2026 12:36 pm | Daniel Arias | Stifel Nicolaus | $700.00 | $606.50 | TheFly | Thermo Fisher price target raised to $700 from $583 at Stifel |
| January 5, 2026 2:55 pm | Vijay Kumar | Evercore ISI | $650.00 | $605.83 | TheFly | Thermo Fisher price target raised to $650 from $610 at Evercore ISI |
| December 15, 2025 11:30 am | — | Wells Fargo | $675.00 | $571.99 | TheFly | Thermo Fisher price target raised to $675 from $635 at Wells Fargo |
| December 9, 2025 9:27 am | Evie Koslosky | Goldman Sachs | $685.00 | $568.21 | TheFly | Thermo Fisher initiated with a Buy at Goldman Sachs |
| December 7, 2025 11:55 pm | Paul Knight | KeyBanc | $750.00 | $572.77 | TheFly | Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc |
| October 29, 2025 2:08 pm | — | Argus Research | $610.00 | $570.82 | TheFly | Thermo Fisher price target raised to $610 from $580 at Argus |
Latest News for TMO
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher heads into Q1 earnings with Life Sciences Solutions growth in focus, as bioproduction strength and new innovations may drive results.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. Building on the trusted legacy of Applied…
Assetmark Inc. grew its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 22.9% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 37,654 shares of the medical research company's stock after buying an additional 7,023 shares during the period. Assetmark Inc.'s holdings in Thermo Fisher
Consolidated Investment Group LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 21.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,730 shares of the medical research company's stock after selling 3,000 shares during the quarter. Thermo
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.